LakeShore Biopharma CoLSBCF Gross Margin % is 82.27% as of Mar. 2025, which is 6% above its 10-year median of 77.68. The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, LakeShore Biopharma Co ranks better than 74.53% on this metric.
LSBCF's Gross Margin % is ranked better than 74.53% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs LSBCF: 82.48
LakeShore Biopharma Co had a gross margin of 82.27% for the quarter that ended in Mar. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for LakeShore Biopharma Co was 0.00% per year.
LakeShore Biopharma Co (OTCPK:LSBCF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
LakeShore Biopharma Co had a gross margin of 82.27% for the quarter that ended in Mar. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
LakeShore Biopharma Co Gross Margin % Related Terms
LakeShore Biopharma Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for LakeShore Biopharma Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSBCF vs ACUT, PPCB, ENSC: Gross Margin % Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
LakeShore Biopharma Co (LSBCF) has a Gross Margin % of 82.27% as of Mar. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on LakeShore Biopharma Co and its competitors. This is near median its historical median of 77.68. Over the past decade, LakeShore Biopharma Co's Gross Margin % has ranged from 76.72 to 82.48. According to the industry distribution chart, LakeShore Biopharma Co ranks #188 out of 738 companies in the Biotechnology industry, placing it in the top 25.5%.
Is LakeShore Biopharma Co's Gross Margin % too high?
LakeShore Biopharma Co's current Gross Margin % of 82.27% is near median its 10-year median of 77.68. Over the past 10 years, this metric has ranged from a low of 76.72 to a high of 82.48. The Biotechnology industry median Gross Margin % is 60.94. LakeShore Biopharma Co's value of 82.27% is 35% above this industry median. Based on the distribution chart, LakeShore Biopharma Co ranks #188 out of 738 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's Gross Margin % compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #188 out of 738 companies for Gross Margin %. This puts LakeShore Biopharma Co in the upper half of its industry. The industry median Gross Margin % is 60.94. LakeShore Biopharma Co's value of 82.27% is 35% above this benchmark. Historically, LakeShore Biopharma Co's own Gross Margin % has ranged from 76.72 to 82.48 over the past decade. While the company's 10-year median is 77.68 vs. the industry median of 60.94, LakeShore Biopharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Gross Margin % of 82.27% is 35% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Gross Margin % is 82.27%, which is near median its own 10-year median of 77.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Gross Margin % of 82.27%. The current Gross Margin % is 82.27%, which is near median its 10-year median of 77.68 and 35% above the Biotechnology industry median of 60.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Gross Margin % is 82.27% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 